Dhein S, Schott M, Gottwald E, Klaus W
Institute für Pharmakologie, Universität zu Köln, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Jul;352(1):94-101. doi: 10.1007/BF00169195.
Quinidine and verapamil are widely used as antiarrhythmic agents and their combination is often used in the treatment of supraventricular tachycardia. This study was undertaken to clarify, whether these drugs exert proarrhythmic effects on the ventricles in therapeutic concentrations and whether possible arrhythmogenic effects might be enhanced by combination. Isolated rabbit hearts perfused according to the Langendorff technique were treated with increasing concentrations of quinidine (0.05 to 3.5 microM) or verapamil (5 to 50 nM) or of their combination (70:1 or 10:1, quinidine:verapamil) corresponding to common low, medium and high free therapeutic concentrations. The epicardial activation process was measured using a computer assisted mapping system for unipolar multichannel recording (256 channels simultaneously). Both substances prolonged the atrioventricular conduction time PQ. This effect was even more pronounced if the 70:1 combination was administered. The activation pattern was altered by both drugs and their combination to the same extent as became obvious from analysis of local activation vectors and of localisation of breakthroughpoints of epicardial activation for heart beats under control conditions and under drug treatment. The epicardial potential durations were prolonged by quinidine and to the same degree by the combinations, but not by verapamil alone. The total activation time was prolonged under the influence of quinidine and if the 70:1 combination was given. Both substances exerted a negative inotropic effect which was enhanced in an additive manner if both drugs were combined. In parallel the coronary flow was diminished.(ABSTRACT TRUNCATED AT 250 WORDS)
奎尼丁和维拉帕米作为抗心律失常药物被广泛使用,它们的联合用药常用于治疗室上性心动过速。本研究旨在阐明这些药物在治疗浓度下是否对心室产生促心律失常作用,以及联合用药是否可能增强潜在的致心律失常效应。采用Langendorff技术灌注的离体兔心,分别用递增浓度的奎尼丁(0.05至3.5微摩尔)、维拉帕米(5至50纳摩尔)或它们的联合用药(奎尼丁:维拉帕米为70:1或10:1)进行处理,这些浓度对应常见的低、中、高游离治疗浓度。使用计算机辅助单极多通道记录(同时记录256个通道)的标测系统测量心外膜激动过程。两种药物均延长房室传导时间PQ。如果给予70:1的联合用药,这种效应更为明显。两种药物及其联合用药均改变激动模式,从对照条件下和药物处理下心外膜激动的局部激动向量分析和突破点定位可明显看出,改变程度相同。奎尼丁延长心外膜电位持续时间,并与联合用药延长的程度相同,但维拉帕米单独使用时则不然。在奎尼丁的影响下以及给予70:1联合用药时,总激动时间延长。两种药物均产生负性肌力作用,如果两种药物联合使用,负性肌力作用会以相加的方式增强。同时,冠状动脉血流量减少。(摘要截短于250字)